Inflammation News and Research

RSS

Damaging DNA builds up in the eyes to drive blinding age-related macular degeneration

Damaging DNA builds up in the eyes of patients with geographic atrophy, an untreatable, poorly understood form of age-related macular degeneration that causes blindness, new research from the University of Virginia School of Medicine reveals.

1 Oct 2021

New approach reveals ‘protein partners’ that may contribute to unusual pathologies of COVID-19

COVID-19 not only causes symptoms characteristic of a typical respiratory disorder, but has also been known to trigger a wide range of other symptoms in people who had been infected, some lasting even long after individuals test negative for the virus.

30 Sep 2021

Dual therapy improves cardiac outcomes in pediatric patients suffering from MIS-C

A recent study by a multidisciplinary team of cardiologists and infectious disease specialists at Children's Hospital Colorado (Children's Colorado) found that pediatric patients suffering from Multisystem Inflammatory Syndrome (MIS-C) who received initial, intensified therapy consisting of intravenous immunoglobulin (IVIG) plus Infliximab had improved cardiac outcomes versus those who received IVIG alone.

30 Sep 2021

Epigenomic analysis reveals biological signatures specific to each pain category

Many people are confronted with chronic pain that can last for months or even years. How to best treat chronic pain? First, pain must be categorized for the right treatment to be prescribed.

30 Sep 2021

Scientists use new technique to study the effects of reactive electrophilic drugs

In 2014, the European Medicines Agency approved the drug Tecfidera for the treatment of relapsing multiple sclerosis, a neurodegenerative disease that affects millions of people worldwide. In multiple sclerosis, inflammation damages the protective myelin insulation around nerves, and the nerves themselves.

30 Sep 2021

The applications of nanomaterials against viral disease

The application of nanomaterials in the diagnosis, prevention, and treatment of viral diseases is reviewed in detail, highlighting areas of significant progress or stagnation from the past few decades.

30 Sep 2021

Aquaporin 5 induction may be a potential therapy to accelerate resurfacing of corneal defects

Corneal defects often heal themselves, but serious injuries that are left untreated can result in inflammation, infection, ulceration and even blindness.

30 Sep 2021

Study investigates the mechanism underlying kidney damage in COVID-19 patients

A review article published in the journal Frontiers in Physiology by researchers affiliated with the Federal University of São Paulo in Brazil discusses the mechanisms whereby SARS-CoV-2 damages the kidneys, potentially serving as a basis for further research in pursuit of treatments to prevent severe renal problems and even chronic kidney disease in COVID-19 patients.

29 Sep 2021

Buck Institute receives $14 million NIH grant to focus on one of the major drivers of aging

Buck Institute professors Judith Campisi, PhD and Lisa Ellerby PhD, have been awarded a $14.3 million grant from the NIH's National Institute of Aging to study cellular senescence, one of the major hallmarks of aging, as a driver of Alzheimer's disease and other age-related dementias.

29 Sep 2021

Peripheral nerve injuries and severe COVID-19

An interesting new study discusses the occurrence of peripheral nerve injuries in a subset of patients who survived severe COVID-19.

29 Sep 2021

Combination of two drugs may help pancreatic and liver cancer patients

A drug candidate discovered and developed decades ago in the laboratory of UC Davis distinguished professor Bruce Hammock may help control the body's raging and often deadly inflammatory response to chemotherapy treatments, especially for pancreatic and liver cancer patients.

29 Sep 2021

Study reports on ex vivo drug delivery system for delivering MSCs to kidney disease patients

Scientists are reporting promising results in the early stages of a clinical trial designed to gauge the feasibility of a new type of treatment for people with acute kidney disease.

28 Sep 2021

Clinical study tests novel topical corneal epithelial stem cell-derived product for treating dry eye disease

Several studies conducted over the last decade have concluded that dry eye disease (DED) affects up to 50% of the U.S. population, creating a liability for the nation's health care system that is estimated to exceed $50 billion annually.

28 Sep 2021

Primary sclerosing cholangitis: Therapy with synthetic bile acid acts directly on the immune system

Primary Sclerosing Cholangitis (PSC) is a rare, chronic inflammatory disease of the bile ducts and is difficult to treat. Studies conducted by the Division of Gastroenterology and Hepatology at MedUni Wien under the guidance of Michael Trauner (Department of Internal Medicine III) were able to show positive effects from the administration of synthetically produced bile acids and bile acid receptor agonists.

28 Sep 2021

Caspase-11 identified as regulator of inflammatory pathology in SARS-CoV-2 infections

New findings identify CASP4/11 as detrimental to inflammation and coagulopathy associated with SARS-CoV-2 infection.

28 Sep 2021

Researchers discover working mechanism of potential drug targets for COVID-19

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases such as cancer, rheumatoid arthritis, and even COVID-19.

28 Sep 2021

Drug treatment decreases risk for severe COVID-19 outcomes in patients with Type 2 diabetes

A type of drug already used to treat obesity and Type 2 diabetes, when taken six months prior to the diagnosis of COVID-19, was associated with a decreased risk of hospitalization, respiratory complications and death in COVID-19 patients with Type 2 diabetes, according to researchers at Penn State College of Medicine.

27 Sep 2021

Inflammation News and Research

Damaging DNA builds up in the eyes to drive blinding age-related macular degeneration

New approach reveals ‘protein partners’ that may contribute to unusual pathologies of COVID-19

Dual therapy improves cardiac outcomes in pediatric patients suffering from MIS-C

Epigenomic analysis reveals biological signatures specific to each pain category

Scientists use new technique to study the effects of reactive electrophilic drugs

The applications of nanomaterials against viral disease

Aquaporin 5 induction may be a potential therapy to accelerate resurfacing of corneal defects

Study investigates the mechanism underlying kidney damage in COVID-19 patients

Buck Institute receives $14 million NIH grant to focus on one of the major drivers of aging

Peripheral nerve injuries and severe COVID-19

Combination of two drugs may help pancreatic and liver cancer patients

Study reports on ex vivo drug delivery system for delivering MSCs to kidney disease patients

Clinical study tests novel topical corneal epithelial stem cell-derived product for treating dry eye disease

Primary sclerosing cholangitis: Therapy with synthetic bile acid acts directly on the immune system

Caspase-11 identified as regulator of inflammatory pathology in SARS-CoV-2 infections

Researchers discover working mechanism of potential drug targets for COVID-19

Drug treatment decreases risk for severe COVID-19 outcomes in patients with Type 2 diabetes

Researchers identify key molecules that may help combat inflammatory diseases

Third COVID-19 mRNA vaccine booster dose indicated for myelofibrosis patients

New study clears a pharmacologic hurdle in developing molecularly targeted therapies for AML

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News